Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis

Hepatic Hepatocyte Nuclear Factor 4α Is Essential for Maintaining Triglyceride and Cholesterol Homeostasis

(2010) Liya Yin et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

AKR1B7 Is Induced by the Farnesoid X Receptor and Metabolizes Bile Acids

(2010) Daniel R. Schmidt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Identification of Novel Pathways That Control Farnesoid X Receptor-mediated Hypocholesterolemia

(2009) Yanqiao Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis

(2009) Songwen Zhang et al.   JOURNAL OF HEPATOLOGY

Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/−and apoE−/−mice

(2009) Helen B. Hartman et al.   JOURNAL OF LIPID RESEARCH

Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)

(2009) Brenton Flatt et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Aldo-Keto Reductase Akr1b7 Gene Is a Common Transcriptional Target of Xenobiotic Receptors Pregnane X Receptor and Constitutive Androstane Receptor

(2009) M.-J. Liu et al.   MOLECULAR PHARMACOLOGY

Antiatherosclerotic effect of farnesoid X receptor

(2008) Andrea Mencarelli et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Routes to 4-Hydroxynonenal: Fundamental Issues in the Mechanisms of Lipid Peroxidation

(2008) Claus Schneider et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Farnesoid X Receptor Deficiency in Mice Leads to Increased Intestinal Epithelial Cell Proliferation and Tumor Development

(2008) R. R.M. Maran et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS